Biosimilars

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.

Get Your Questions Answered on Biosimilar Therapies

Dec. 7, 2017

Join inflammatory bowel disease (IBD) experts on Dec. 11, 2017, 8-8:45 p.m. ET, for a free webinar on biosimilar therapies.

Can You Explain Biosimilars to Patients?

Oct. 25, 2017

AGA is taking the lead in educating health care professionals and their patients about biosimilars and how they can play a role in IBD patient care.

Advent of Biosimilar Products in US GI Practice

July 19, 2017

Advent of Biosimilar Products in US GI Practice
Advertisement

Considerations in Use of Biosimilars for Gastrointestinal Disorders

July 19, 2017

Considerations in Use of Biosimilars for Gastrointestinal Disorders

AGA Makes Six Recommendations to FDA on Interchangeable Biosimilars

May 25, 2017

AGA provides guidance to FDA to ensure patient safety and empower physicians.

DDW® Symposium Will Focus on Biosimilars

May 3, 2017

AGA and the Crohn’s and Colitis Foundation will co-host a DDW Symposium on Biosimilars on Tuesday, May 9, from 2 to 3:30 p.m.

Biosimilars in IBD: The Outlook in 2017

March 6, 2017

Concerns around biosimilars are discussed in this AGA-MedPage Today Reading Room article, including extrapolation and interchangeability.